Biostage, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.89 million compared to USD 2.18 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.2 a year ago.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.921 USD | -0.31% |
|
+11.49% | -41.46% |
1st Jan change | Capi. | |
---|---|---|
-41.46% | 41.81M | |
+4.18% | 211B | |
+8.00% | 185B | |
+31.86% | 158B | |
+33.21% | 113B | |
+2.28% | 64.32B | |
+21.14% | 55.66B | |
+0.11% | 48.41B | |
-6.76% | 37.82B | |
+0.78% | 35.57B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023